Bayer HealthCare Selects Tripos to Provide Drug Discovery Software For Its Global Enterprise
Tripos, Inc. and Bayer HealthCare AG have agreed to deploy Tripos’ proprietary discovery informatics software, SYBYL and UNITY, globally across Bayer’s drug discovery and development organization. Under the terms of the agreement, Tripos will provide Bayer with license rights to SYBYL and UNITY for its sites in Germany and the United States that are focused on the discovery and development of new therapeutics. Financial terms of the agreement were not disclosed.
The SYBYL computational chemistry and molecular modeling system is the heart of Tripos’ discovery software offering, providing the fundamental components for research scientists to understand molecular structure and properties, with a special focus on the creation of new chemical entities. UNITY adds functionality to SYBYL with rapid, conformationally-flexible three-dimensional searching of chemical and biological databases.
“The seamless integration of cheminformatics, pharmacophore modeling and protein structure-based design tools offered by Tripos’ software products will help us focus our synthesis efforts on promising compounds,” said Dr. Hanno Wild, vice president for medicinal chemistry at Bayer HealthCare.
Dr. Alexander Hillisch, head of computational chemistry at Bayer HealthCare AG, added, “Tripos’ ability to offer a complete computational chemistry suite, including sophisticated high-throughput docking programs on the Linux platform, was a critical factor in our choice.”
“We are excited to welcome Bayer HealthCare to the list of customers that have embraced our core business strategy of providing one of the most integrated drug discovery offerings available,” said Dr. John P. McAlister, president and CEO of Tripos. “Our range of scientific expertise combined with our innovative technological capabilities enables us to provide the breadth of informatics products and services and discovery research offerings our customers need to accomplish their goals.”